Citations

Clear

1320 citation(s) found for "Nguyen, Vi".

Clinical features of shiitake dermatitis: a systematic review
Nguyen, Austin Huy , Gonzaga, Maria I., Lim, Victoria M. , Adler, Michael J., Mitkov, Mario , Cappel, Mark A. , Mitkov, Mario V.

Mayo Clinic

International Journal of Dermatology | January 5, 2017 | Volume: 56 | Issue: 6 | Pages: 610-616

10.1111/ijd.13433 | PMID 28054338 Get It

SummaryShiitake dermatitis is a rare cutaneous reaction to lentinan, a polysaccharide component in the cell walls of shiitake mushrooms (Lentinula edodes). Herein, we systematically review the case report and case series English‐language literature on shiitake dermatitis, which refers to a total of 50 patients (38 males, 12 females; mean age: 44.58 years). The majority of cases occurred after the consumption of raw mushrooms, whereas 22% of cases were caused by the eating of lightly or undercooked mushrooms. The most common clinical presentations, localized symptoms, and systemic findings include linear flagellated dermatitis (98%), pruritus (78%), and fever, diarrhea, and mucosal ulcers, respectively. The diagnosis of this entity continues to be based on clinical findings as laboratory abnormalities, and the findings of skin biopsies and patch/prick tests are nonspecific and inconsistent. The condition is self‐limiting, resolving in approximately 12.5 d without treatment. Based on the included case reports, it appears that medical treatment may slightly shorten the course of disease (to 9–11 d, varying by therapy) but should be considered on an individual patient basis. However, the treatment of symptoms, reassurance, and the avoidance of re‐exposure are sufficient treatment recommendations for this condition.
Comparison of longterm outcomes and quality of life in recipients of donation after cardiac death liver grafts with a propensity‐matched cohort
Croome, Kristopher P. , Lee, David D. , Perry, Dana K. , Burns, Justin M. , Nguyen, Justin H. , Taner, C. Burcin , Keaveny, Andrew P. , Croome, Kris P , Lee, David D

Mayo Clinic

Liver Transplantation | December 27, 2016 | Volume: 23 | Issue: 3 | Pages: 342-351

10.1002/lt.24713 | PMID 28027600 Get It

The use of liver grafts from donation after cardiac death (DCD) has been limited due to the increased rate of graft failure, mostly related to ischemic cholangiopathy (IC). It is our hypothesis that longterm outcomes and quality of life (QOL) similar to patients undergoing liver transplantation (LT) with donation after brain death (DBD) can be achieved. Clinical outcomes of all patients undergoing DCD LT (n = 300) between 1998 and 2015 were compared with a propensity score–matched cohort of patients undergoing DBD LT (n = 300). Patients were contacted for a follow‐up questionnaire and short‐form (SF)–12 QOL Survey administration. Median follow‐up was >5 years. Graft survival at 1‐, 3‐, and 5‐years was 83.8%, 75.5%, and 70.1% in the DCD LT group and 88.4%, 80.3%, and 73.9% in the DBD LT group ( P = 0.27). Patient survival at 1‐, 3‐, and 5‐years was 92.3%, 86.1%, and 80.3% in the DCD LT group and 92.3%, 85.1%, and 79.5% in the DBD LT group ( P = 0.81). IC developed in 11.7% and 2% of patients in the DCD LT group and DBD LT group, respectively ( P < 0.001). DCD LT recipients who developed IC had inferior graft survival compared with both the DCD non‐IC group ( P < 0.001) and the DBD LT group ( P < 0.001); no difference in graft survival was observed between the DCD non‐IC group and the DBD LT group ( P = 0.50). Physical and Mental Composite Scores on the SF‐12 QOL questionnaire were similar between the DCD LT and DBD LT groups (44.0 versus 45.4; P = 0.34 and 51.9 versus 52.2; P = 0.83), respectively. Similar longterm survival and QOL scores can be achieved between DCD LT and DBD LT. Prevention of IC in DCD LT yields excellent graft and patient survival with virtually no difference compared with DBD LT. Liver Transplantation 23 342–351 2017 AASLD .
Gliosarcoma with Primary Skull Base Invasion
Nguyen, Quoc‐Bao D. , Perry, Avital , Graffeo, Christopher S. , Jentoft, Mark E. , Morris, Padraig P., Gompel, Jamie J. Van , Nesvick, Cody L. , O'Neill, Brian P, Van Gompel, Jamie J , Raghunathan, Aditya , O’Neill, Brian Patrick , Morris, Jonathan M.

Mayo Clinic

Case Reports in Radiology | December 8, 2016 | Volume: 2016 | Issue: No issue available | Pages: 1-6

10.1155/2016/1762195 | PMID 28053799 Get It

Gliosarcoma is an uncommon variant of glioblastoma, which commonly demonstrates dural attachment. However, skull base invasion is rarely seen with this entity. Herein, we report a 44-year-old female patient diagnosed with primary intracranial gliosarcoma extensively invading the skull base and muscles of mastication. She presented to our institution with a three-month history of difficult right jaw opening and retro-orbital pressure and one week of severe right-sided postauricular headache. Head CT demonstrated a 6 cm mass with marked bony erosion. Brain MRI at a one-week interval more clearly characterized tumor extension through the right orbit and muscles of mastication, with overall growth to 7 cm and worsening midline shift. The patient underwent a right frontotemporal craniotomy for gross total resection. Pathology confirmed the diagnosis of gliosarcoma, IDH-wildtype (WHO grade IV). Her postoperative course was uneventful and she was discharged at preoperative neurologic baseline. To our knowledge, this is the third reported case of a primary intracranial gliosarcoma with direct invasion of skull base, brain parenchyma, and extracranial compartment. However, this is the first report case of primary GS invading the surrounding musculature and orbit. This case report highlights the rapid aggressiveness of gliosarcomas and further a prior undescribed radiographic and anatomic finding of skull base invasion with this entity.
A candidate regulatory variant at the TREM gene cluster associates with decreased Alzheimer's disease risk and increased TREML1 and TREM2 brain gene expression
Carrasquillo, Minerva M., Allen, Mariet , Burgess, Jeremy D. , Wang, Xue , Strickland, Samantha L. , Aryal, Shivani , Siuda, Joanna , Kachadoorian, Michaela, Medway, Christopher, Younkin, Curtis, Nair, Asha, Chanana, Pritha , Serie, Daniel, Nguyen, Thuy , Lincoln, Sarah, Malphrus, Kimberly G., Morgan, Kevin , Golde, Todd E. , Price, Nathan D. , White, Charles C. , Jager, Philip L. De , Bennett, David A. , Asmann, Yan W. , Petersen, Ronald , Graff‐Radford, Neill R., Younkin, Steven G., Ertekin‐Taner, Nilüfer , Kachadoorian, Michaela L, Younkin, Curtis S, Crook, Julia E. , Bennett, David A. , Carrasquillo, Minerva M. , Siuda, Joanna S. , Wang, Chen , Graff‐Radford, Neill R., Dickson, Dennis W. , Price, Nathan D

Mayo Clinic

Alzheimer's & Dementia | December 8, 2016 | Volume: 13 | Issue: 6 | Pages: 663-673

10.1016/j.jalz.2016.10.005 | PMID 27939925 Get It

AbstractIntroductionWe hypothesized that common Alzheimer's disease (AD)‐associated variants within the triggering receptor expressed on myeloid (TREM) gene cluster influence disease through gene expression.MethodsExpression microarrays on temporal cortex and cerebellum from ∼400 neuropathologically diagnosed subjects and two independent RNAseq replication cohorts were used for expression quantitative trait locus analysis.ResultsA variant within a DNase hypersensitive site 5′ of TREM2, rs9357347‐C, associates with reduced AD risk and increased TREML1 and TREM2 levels (uncorrected P = 6.3 × 10−3 and 4.6 × 10−2, respectively). Meta‐analysis on expression quantitative trait locus results from three independent data sets (n = 1006) confirmed these associations (uncorrected P = 3.4 × 10−2 and 3.5 × 10−3, Bonferroni‐corrected P = 6.7 × 10−2 and 7.1 × 10−3, respectively).DiscussionOur findings point to rs9357347 as a functional regulatory variant that contributes to a protective effect observed at the TREM locus in the International Genomics of Alzheimer's Project genome‐wide association study meta‐analysis and suggest concomitant increase in TREML1 and TREM2 brain levels as a potential mechanism for protection from AD.
Population Pharmacokinetics and Exposure–Response Relationship of Carfilzomib in Patients With Multiple Myeloma
Ou, Ying , Doshi, Sameer , Nguyen, Anh H. , Jönsson, Fredrik , Aggarwal, Sanjay , Rajangam, Kanya, Dimopoulos, Meletios Α. , Stewart, A. Keith, Badros, Ashraf , Papadopoulos, Kyriakos P. , Vij, Ravi , Niesvizky, Rubén, Graham, Richard, Visich, Jenn, Siegel, David S. , Jagannath, Sundar , Dimopoulos, Meletios A

Mayo Clinic

The Journal of Clinical Pharmacology | December 7, 2016 | Volume: 57 | Issue: 5 | Pages: 663-677

10.1002/jcph.850 | PMID 27925676 Get It

AbstractA population pharmacokinetic (PK) model and exposure–response (E‐R) analysis was developed using data collected from 5 phase 1b/2 and 2 phase 3 studies in subjects with multiple myeloma. Subjects receiving intravenous infusion on 2 consecutive days each week for 3 weeks (days 1, 2, 8, 9, 15, and 16) in each cycle at doses ranging from 15 to 20/56 mg/m2 (20 mg/m2 in cycle 1 and, if tolerated, escalated to 56 mg/m2 on day 8 of cycle 1). The population PK analysis indicated that among all the covariates tested, the only statistically significant covariate was body surface area on carfilzomib clearance; however, this covariate was unlikely to be clinically significant. Despite inclusion of different populations (relapsed or relapsed/refractory), treatments (carfilzomib monotherapy or combination therapy), infusion lengths (2 to 10 minutes or 30 minutes), and different doses, the E‐R analysis of efficacy showed that after adjusting for baseline characteristics, higher area under the concentration–time curve was associated with improved overall response rate (ORR), from 15 to 20/56 mg/m2. No positive relationships between maximum concentration and ORR were identified, indicating that ORR would not be expected to be impacted by infusion length. For safety end points, no statistically significant relationship between exposure and increasing risk of adverse events was identified. The results of an E‐R analysis provided strong support for a carfilzomib dose at 20/56 mg/m2 as a 30‐minute infusion for monotherapy and combination therapy. This article illustrates an example of application of E‐R analysis to support labeling dose recommendation in the absence of extensive clinical data.
Predictors of Complications After Percutaneous Image-Guided Renal Cryoablation for T1a Renal Cortical Neoplasms
Okhunov, Zhamshid , Moreira, Daniel M. , Junco, Michael del , Abedi, Garen , Lobko, Igor , Kaler, Kamaljot S. , Nguyen, Nobel D., Youssef, Ramy F. , Uchio, Edward , Kavoussi, Louis R., Landman, Jaime, Nguyen, Nobel

Mayo Clinic

Journal of Endourology | October 26, 2016 | Volume: 31 | Issue: 1 | Pages: 7-13

10.1089/end.2016.0684 | PMID 27784185 Get It

An Unusual Suspect: Lymphoepithelial Cyst of the Pancreas
Adike, Abimbola , Horsley‐Silva, Jennifer L. , Deval, Neha, Conley, Christopher R., Lam‐Himlin, Dora , Lam-Himlin, Dora M, Nguyen, Cuong Cao

Mayo Clinic

Case Reports in Gastrointestinal Medicine | October 26, 2016 | Volume: 2016 | Issue: No issue available | Pages: 1-3

10.1155/2016/5492824 | PMID 27847656 Get It

Lymphoepithelial cysts (LECs) of the pancreas are benign, rare pancreatic cysts that are found predominantly in men. These cysts can present as a diagnostic conundrum given their rarity and difficulty of distinguishing these cysts from those with malignant potential. We present an incidental case of a LEC in a middle-aged man.
Early satiety and postprandial fullness in gastroparesis correlate with gastroparesis severity, gastric emptying, and water load testing
Hallinan, Erin, Farrugia, Gianrico , Koch, K L, Snape, William J., McCallum, Richard W. , Sarosiek, Irene , Pasricha, Pankaj J. , Clarke, John O. , Miriel, Laura , Tonascia, James , Hamilton, Frank A., Clarke, J , Parkman, Henry P. , Hasler, William L. , Nguyen, Linda Anh B. , Abell, Thomas L.

Mayo Clinic

Neurogastroenterology & Motility | October 26, 2016 | Volume: 29 | Issue: 4 | Pages: No page available

10.1111/nmo.12981 | PMID 27781342 Get It

AbstractBackgroundEarly satiety (ES) and postprandial fullness (PPF) are often present in gastroparesis, but the importance of these symptoms in gastroparesis has not been well‐described. The aims were: (i) Characterize ES and PPF in patients with gastroparesis. (ii) Assess relationships of ES and PPF with etiology of gastroparesis, quality of life, body weight, gastric emptying, and water load testing.MethodsGastroparetic patients filled out questionnaires assessing symptoms (PAGI‐SYM) and quality of life (PAGI‐QOL, SF‐36v2). Patients underwent gastric emptying scintigraphy and water load testing.Key Results198 patients with gastroparesis (134 IG, 64 DG) were evaluated. Early satiety was severe or very severe in 50% of patients. Postprandial fullness was severe or very severe in 60% of patients. Severity scores for ES and PPF were similar between idiopathic and diabetic gastroparesis. Increasing severity of ES and PPF were associated with other gastroparesis symptoms including nausea/vomiting, satiety/early fullness, bloating, and upper abdominal pain and GERD subscores. Increasing severity of ES and PPF were associated with increasing gastroparesis severity, decreased BMI, decreased quality of life from PAGI‐QOL and SF‐36 physical health. Increasing severity of ES and PPF were associated with increasing gastric retention of a solid meal and decreased volume during water load test.Conclusions & InferencesEarly satiety and PPF are commonly severe symptoms in both diabetic and idiopathic gastroparesis. Early satiety and PPF severity are associated with other gastroparesis symptom severities, body weight, quality of life, gastric emptying, and water load testing. Thus, ES and PPF are important symptoms characterizing gastroparesis. ClinicalTrials.gov number: NCT NCT01696747.
O2‐10‐04: A Regulatory Variant at the TREM Gene Cluster Associates with Decreased Alzheimer’s Disease Risk and Increased TREML1 and TREM2 Brain Gene Expression
Carrasquillo, Minerva M. , Allen, Mariet , Strickland, Samantha L. , Aryal, Shivani , Kachadoorian, Michaela, Medway, Christopher, Younkin, Curtis, Nair, Asha, Chanana, Pritha , Wang, Xue , Serie, Daniel, Nguyen, Thuy , Lincoln, Sarah, Malphrus, Kimberly G., Golde, Todd E. , Jager, Philip L. De , Asmann, Yan W. , Younkin, Steven G., Ertekin‐Taner, Nilüfer , Carrasquillo, Minerva M. , Burgess, Jeremy D. , Siuda, Joanna S. , Morgan, Kevin , Price, Nathan D. , White, Charles, Soni, Rajesh K , Crook, Julia E. , Dickson, Dennis W.

Mayo Clinic

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_5 | Pages: No page available

10.1016/j.jalz.2016.06.451 Get It